| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7374747 | MYLAN | Pharmaceutical foam |
Jan, 2024
(3 months from now) | |
| US7141237 | MYLAN | Pharmaceutical foam |
Feb, 2024
(4 months from now) | |
Evoclin is owned by Mylan.
Evoclin contains Clindamycin Phosphate.
Evoclin has a total of 2 drug patents out of which 0 drug patents have expired.
Evoclin was authorised for market use on 22 October, 2004.
Evoclin is available in aerosol, foam;topical dosage forms.
Evoclin can be used as treatment of acne vulgaris.
The generics of Evoclin are possible to be released after 03 February, 2024.
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 22 October, 2004
Treatment: Treatment of acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
EVOCLIN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic